Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.07 – $2.05
57% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.71B | $1.79B | $1.88B | $2.15B | $3.29B | $4.35B | $4.38B | $3.87B |
| Cost of revenue | $481.0M | $492.0M | $492.0M | $591.0M | $1.50B | $1.96B | $2.01B | $1.59B |
| Gross profit | $1.23B | $1.30B | $1.30B | $1.28B | $1.79B | $2.39B | $2.37B | $2.28B |
| Gross margin | 71.8% | 72.5% | 69.3% | 59.7% | 54.5% | 55.0% | 54.1% | 58.9% |
| R&D | $998.0M | $812.0M | $689.0M | $713.0M | $735.0M | $877.0M | $1.06B | $1.01B |
| Operating income | −$830.0M | −$1.04B | −$877.0M | −$1.04B | −$1.15B | −$2.02B | −$926.0M | −$1.11B |
| EBITDA | −$118.0M | $683.0M | $873.0M | −$482.0M | $873.0M | −$758.0M | $16.0M | −$492.1M |
| Net income | −$632.0M | −$152.0M | −$59.0M | −$492.0M | −$298.0M | −$1.48B | −$577.0M | $154.0M |
| Net margin | -37.0% | -8.5% | -3.1% | -22.9% | -9.1% | -33.9% | -13.2% | 4.0% |
| EPS (diluted) | -2.94 | -0.71 | -0.27 | -2.29 | -1.39 | -6.99 | -2.73 | 0.73 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $4.7B | $1.25 | $1.14–$1.41 | 1 |
| 2028 | $5.7B | $2.57 | $2.34–$2.89 | 1 |
| 2029 | $6.8B | $3.92 | $3.57–$4.41 | 1 |
| 2030 | $10.2B | $10.37 | $9.45–$11.68 | 1 |
Forward consensus · source: Financial Modeling Prep
CYBERDYNE INC ORD
No one on the platform currently holds CYBQF.
No tracked institution reports a position in CYBQF as of their last filing.
No one on the platform has traded CYBQF yet.
| $122M |
| — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
| MFCSFMedical Facilities Corporation | $12.76 | +0.47% | $224M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.1× historical median P/S.
Fair value ≈ $2.02 · price $1.63 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.